US Pharma MarketingMyqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
Cytokinetics heart drug scores in closely watched trial
<figure><div><img src="https://imgproxy.divecdn.com/O5l3Ak2w-ITPZwAy2_UP-yuYAxNqpRx2E-yOxBQdi8M/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy05MzA1MTIzNTAuanBn.webp"/></div></figure><p>Myqorzo’s su
Source: BioPharma Dive